Breaking News, Financial News

Financial Report: AMRI 3Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AMRI

3Q Revenues: $61.4 million (+29%)

3Q Earnings: $7.0 million (+250%)

YTD Revenues: $172.9 million (+19%)

YTD Earnings: $17.4 million (+78%)

Comments: Total contract revenue for the quarter was $54.1 million (+30%). Discovery Services revenue was $16.4 million (+57%). Development/Small Scale Manufacturing revenue was $14.5 million (+11%). Large Scale Manufacturing revenue was $23.2 million (+29%). Allegra royalties dropped 5% to $5.7 million. Milestone revenue from the company’s licensing agreement with BMS was $1.5 million in the quarter. Earnings also include a $1.2 million adjustment to record income tax benefits from certain R&D activities.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters